Retatrutide Phase 3 Trial Targets Obesity and Cardiovascular Disease
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Abstract
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
NCT ID: NCT05882045
Status: ACTIVE_NOT…